ArticleProceedings of the National Academy of Sciences of the United States of America2026
Estimating US savings on outpatient prescription pharmaceuticals from international reference pricing.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Estimating US savings on outpatient prescription pharmaceuticals from international reference pricing.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
The exorbitant cost of prescription pharmaceuticals is a critical and long-standing concern facing the United States (US). To curb rising drug costs, international reference pricing, aligning drug prices with those in other high-income countries, has emerged as a prominent policy option. We evaluated the potential national savings from such a strategy in the United States through a comprehensive analysis of utilization patterns and global price differentials for over 8,000 drugs. We project an annual national saving of $184 billion if outpatient prescription pharmaceuticals were priced comparably to those in Canada, France, Germany, Japan, and the United Kingdom. Private insurers, Medicare, and Medicaid would realize savings of 51%, 62%, and 35%, respectively. Pharmaceutical expenditures for common chronic illnesses would be substantially reduced, with costs declining by over 75% for diabetes, atrial fibrillation, and heart failure. Our findings emphasize the substantial fiscal and equity gains achievable through international reference pricing, demonstrating its potential to mitigate financial burdens borne by both healthcare systems and individual patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.